ArticleJCO clinical cancer informatics2022
Reply to A. Pfob and C. Sidey-Gibbons.
Abstract readLetterComment
In one paragraph
Article in JCO clinical cancer informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
- Comment on
Authors and funding
9 authors.
Carlos H BarcenasCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-5377-9167
Juhee SongORCID 0000-0002-8688-4104
Rashmi K MurthyCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Akshara S RaghavendraCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6425-4400
Yisheng LiCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9847-8544
Limin HsuCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Robert W CarlsonCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-2011-6695
Debu TripathyCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5711-2404
Gabriel N HortobagyiCarlos H. Barcenas, MD, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Juhee Song, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Rashmi K. Murthy, MD, MBE and Akshara S. Raghavendra, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Yisheng Li, PhD, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; Limin Hsu, MS, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert W. Carlson, MD, National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA, Department of Medicine, Division of Medical Oncology, Stanford University Medical Center, Stanford, CA; and Debu Tripathy, MD and Gabriel N. Hortobagyi, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4873-4412
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsContrast MediaFemaleHumansNeoplasm Recurrence, LocalPrognosisContrast Media
Identifiers
PMID
35175860What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.